Search research articles
Contact Us
Filters
Showing results (1-10 of 41) with videos related to
Page
of 5
Sort By:
Vaccine
|
June 21, 2011
Technology transfer to developing country vaccine manufacturers to improve global influenza vaccine production: a success story and a window into the future
F Marc LaForce
Vaccine
|
April 25, 2012
Critical episodes in the understanding and control of epidemic meningococcal meningitis
Andrew W Artenstein, F Marc LaForce
Vaccine
|
June 6, 2007
The promise of conjugate vaccines for Africa
Marie Paule Kieny, F Marc LaForce
Health Affairs (Project Hope)
|
June 10, 2011
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine
F Marc LaForce, Jean-Marie Okwo-Bele
Journal of Health, Population, and Nutrition
|
December 22, 2004
Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
Montse Soriano-Gabarró, Nancy Rosenstein, F Marc LaForce
Human Vaccines & Immunotherapeutics
|
April 13, 2012
Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)
Carl E Frasch, Marie-Pierre Preziosi, F Marc LaForce
Vaccine
|
May 30, 2009
Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
F Marc LaForce, Neil Ravenscroft, Mamoudou Djingarey, et al.
Human Vaccines & Immunotherapeutics
|
October 20, 2017
Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVac<sup>R</sup>)
Prasad S Kulkarni, Suresh S Jadhav, F Marc LaForce
Vaccine
|
May 25, 2007
The Meningitis Vaccine Project
F Marc LaForce, Kader Konde, Simonetta Viviani, et al.
Human Vaccines & Immunotherapeutics
|
October 3, 2017
Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 41) with videos related to
Sort By:
Page
of 5
Vaccine
|
June 21, 2011
Technology transfer to developing country vaccine manufacturers to improve global influenza vaccine production: a success story and a window into the future
F Marc LaForce
Vaccine
|
April 25, 2012
Critical episodes in the understanding and control of epidemic meningococcal meningitis
Andrew W Artenstein, F Marc LaForce
Vaccine
|
June 6, 2007
The promise of conjugate vaccines for Africa
Marie Paule Kieny, F Marc LaForce
Health Affairs (Project Hope)
|
June 10, 2011
Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine
F Marc LaForce, Jean-Marie Okwo-Bele
Journal of Health, Population, and Nutrition
|
December 22, 2004
Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project
Montse Soriano-Gabarró, Nancy Rosenstein, F Marc LaForce
Human Vaccines & Immunotherapeutics
|
April 13, 2012
Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM)
Carl E Frasch, Marie-Pierre Preziosi, F Marc LaForce
Vaccine
|
May 30, 2009
Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution
F Marc LaForce, Neil Ravenscroft, Mamoudou Djingarey, et al.
Human Vaccines & Immunotherapeutics
|
October 20, 2017
Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVac<sup>R</sup>)
Prasad S Kulkarni, Suresh S Jadhav, F Marc LaForce
Vaccine
|
May 25, 2007
The Meningitis Vaccine Project
F Marc LaForce, Kader Konde, Simonetta Viviani, et al.
Human Vaccines & Immunotherapeutics
|
October 3, 2017
Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps
F Marc LaForce, Mamoudou Djingarey, Simonetta Viviani, et al.
Page
of 5